



A mammalian NudC-like protein essential for dynein stability and cell viability

Citation

Zhou, T., W. Zimmerman, X. Liu, and R. L. Erikson. 2006. "A Mammalian NudC-like Protein Essential for Dynein Stability and Cell Viability." *Proceedings of the National Academy of Sciences* 103 (24): 9039–44. <https://doi.org/10.1073/pnas.0602916103>.

Published version

<https://doi.org/10.1073/pnas.0602916103>

Link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:41534331>

Terms of use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at

<https://harvardwiki.atlassian.net/wiki/external/NGY5NDE4ZjgzNTc5NDQzMGIzZWZhMGFIOWI2M2EwYTg>

Accessibility

<https://accessibility.huit.harvard.edu/digital-accessibility-policy>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#)

A mammalian NudC-like protein essential for dynein stability and cell viability

Tianhua Zhou*, Wendy Zimmerman, Xiaoqi Liu†, and Raymond L. Erikson‡

Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138

Contributed by Raymond L. Erikson, April 27, 2006

Cytoplasmic dynein, a minus-end-directed microtubule motor, has been implicated in many fundamental cellular processes; however, little is known regarding the underlying molecular machinery that regulates its stability. In *Aspergillus nidulans*, nuclear distribution gene C (*nudC*) has been implicated in the regulation of dynein-mediated nuclear migration. Here, we characterize a previously undescribed mammalian NudC-like protein (NudCL). The expression and phosphorylation of NudCL are increased during mitosis. Depletion of NudCL by RNA interference in HeLa cells inhibits cell growth and induces mitotic arrest with multiple mitotic defects, which subsequently result in cell death. Unexpectedly, the majority of NudCL depletion-induced mitotic defects may result from loss of dynein function; this interpretation is supported by the failure to recruit sufficient γ -tubulin to spindle poles and the mislocalization of the dynein complex from kinetochores, spindle microtubules, and spindle poles during mitosis. Depletion of NudCL also results in the aggregation of dynein intermediate chain throughout the cytoplasm during mitosis. NudCL was shown to bind to the dynein complex, and its depletion induces degradation of dynein intermediate chain, a process suppressed by MG132, a proteasome inhibitor. Taken together, these data suggest a previously undescribed mechanism whereby NudCL appears to influence the stabilization of dynein intermediate chain.

chaperone | mitosis | proteasome | degradation | aggregation

Cytoplasmic dynein is a microtubule-associated minus-end-directed motor involved in many fundamental cellular processes, including nuclear migration, mitosis, maintenance of the Golgi apparatus, and intracellular trafficking (1, 2). Mammalian cytoplasmic dynein is a massive multisubunit complex composed of two heavy chains, several intermediate chains, light-intermediate chains, and various light chains (2, 3). This complexity allows cytoplasmic dynein to be regulated in subtle ways at multiple levels. At a molecular level, the regulation of cytoplasmic dynein has two major modes: regulation of its subunits and regulation through accessory proteins (2, 3). Among these associated regulators, the multisubunit dynactin complex plays a general regulatory role in cargo binding and processive movement of dynein (2).

Studies of nuclear migration in the fungus, *Aspergillus nidulans*, have uncovered at least seven different nuclear distribution (*nud*) genes (4). The characterization of *nud* mutants in *A. nidulans* that prevent nuclear migration into the mycelium revealed that the cytoplasmic dynein/dynactin complex is a major contributor to these processes (4). In mammalian cells, most nuclear distribution proteins are components of the cytoplasmic dynein/dynactin complex or appear to regulate dynein function (4, 5). The *nudA*, *nudI*, and *nudG* genes encode cytoplasmic dynein heavy, intermediate, and light chain, respectively, and the proteins encoded by *nudK* and *nudM* are actin-related protein 1 and p150 dynactin, elements of the dynactin complex (4, 6). The mammalian homolog of *nudF* is lissencephaly 1 (Lis1), a mutation that causes human lissencephaly (7). Lis1, together with mNudE/NdeI and NUDEL/Nde1, mammalian homologues of NudE, seems to regulate cytoplasmic dynein (7, 8). A mutation in *Aspergillus nudC* induces the

reduction of the protein level of NudF at restrictive temperature (9). Mammalian NudC associates with Lis1 and the dynein/dynactin complex (10, 11); however, the function of mammalian NudC remains largely unknown.

Recently, we demonstrated that mammalian NudC is required for mitosis and cytokinesis (11). Data from *A. nidulans* show that the *nudC3* mutation greatly reduces the protein level of NudF (9). We sought to determine whether similar events occur in mammalian cells. Our data show that the protein level of Lis1 was not significantly affected by depletion of NudC in HeLa cells, suggesting another homolog of *Aspergillus nudC* in mammalian cells. Here we report a previously undescribed protein that shares significant homology with *Aspergillus* and human NudC. Our data show that this NudC-like protein (NudCL) plays an essential role in mitosis and contributes to stabilization of the dynein complex.

Results

Characterization of NudCL Protein. To identify previously undescribed mammalian NudC homologs, we used the protein sequence of human NudC to search the database of National Center for Biotechnology Information with TBLASTN. We found an uncharacterized human sequence (GenBank; BC035014) homologous to human NudC and cloned this cDNA by RT-PCR with total RNA extracted from HeLa cells. It encoded a deduced 361-aa protein (GenBank; AAH35014) with a predicted molecular mass of 41 kDa; this protein shares significant homology with human NudC (identity, 26.0%; similarity, 59.0%) and *Aspergillus* NudC (identity, 32%; similarity, 50.4%), therefore, we named it NudC-like protein, NudCL. As is the case for *Aspergillus* and human NudC, NudCL has a predicted coiled-coil domain and a nuclear movement domain (pfam03593; National Center for Biotechnology Information) that contains a p23 domain (cd00237; National Center for Biotechnology Information; Fig. 1A).

To characterize the function of NudCL, we raised a rabbit polyclonal antibody against GST-NudCL. After affinity purification, the anti-NudCL antibody specifically recognized NudCL protein (Fig. 7A, which is published as supporting information on the PNAS web site). Immunoblot analysis by using this antibody showed that NudCL protein is ubiquitously expressed (Fig. 7B and C). We also found that, in interphase, NudCL colocalizes with both Golgi matrix protein GM130 and Golgi p58 protein in addition to some punctate distribution throughout the cell (Fig. 8A and B, which is published as supporting information on the PNAS web site). NudCL diffused into the cytoplasm during mitosis and began to reassemble into vesicular structures, as did

Conflict of interest statement: No conflicts declared.

Abbreviations: IC, intermediate chain; Lis1, lissencephaly 1; NudCL, NudC-like protein; RNAi, RNA interference.

*Present address: Department of Medical Genetics, Zhejiang University School of Medicine, Hangzhou 310031, People's Republic of China.

†Present address: Department of Biochemistry, Purdue University, West Lafayette, IN 47907.

‡To whom correspondence should be addressed. E-mail: erikson@mcb.harvard.edu.

© 2006 by The National Academy of Sciences of the USA




Fig. 4. Depletion of NudCL induces the mislocalization and aggregation of the dynein complex. HeLa cells grown on the coverslips were transfected with either pBS/U6 or pBS/U6-NudCL and pBABE-puro at a ratio of 7:1. At 24 h after transfection, puromycin was added to select the transfection-positive cells. At different transfection times cells were fixed with cold methanol and incubated with anti-dynein IC antibody and anti-CREST anti-serum, anti- γ -tubulin, or α -tubulin antibodies. DNA was visualized by DAPI. (Scale bars: 10 μ m.) (A and A') Dynein mislocalization at kinetochores during mitosis. (B and B') Dynein mislocalizes from mitotic spindle poles during mitosis. The spindle poles and centrosomes are indicated by arrowheads and arrows, respectively. (C and C') Dynein appears to aggregate at the centrosomes in interphase. The centrosomes are indicated by arrows. (D and D') Dynein mislocalizes from mitotic spindles. (E and E') Dynein aggregates during mitosis in NudCL-depleted cells.

Depletion of NudCL Induces the Degradation of Dynein IC. Because protein aggregation indicates the existence of misfolded proteins that are prone to degradation by the proteasome pathway (15), we examined the stability of the dynein complex. We found that dynein IC began to decrease significantly at 72 h after transfection of pBS/U6-NudCL and was detected at $\approx 15\%$ of that in control cells at 120 h after transfection, whereas there was no significant change in the level of Lis1 and extracellular signal-regulated kinase 2 (Erk2) (Fig. 6A). To eliminate the possibility of NudCL depletion-induced dynein IC degradation by off-target effects of RNAi, we developed the lentivirus-based RNAi system with a targeting region of NudCL mRNA different from that of the vector-based RNAi. We found that dynein IC decreased considerably in lentivirus-based NudCL-depleted cells, whereas there were no significant changes of Lis1, p150

dynactin, and dynein heavy chain (Fig. 12, which is published as supporting information on the PNAS web site), suggesting that NudCL may be specifically required for the stability of dynein IC in mammalian cells.

To assess whether the degradation of dynein IC in NudCL-depleted cells is related to the proteasome pathway, we added MG132, a proteasome inhibitor (16), into NudCL-depleted cells for 12 h and found that the level of dynein IC was significantly restored (Fig. 6B). Taken together, these results indicate that dynein IC appears to be destroyed via the proteasome pathway in cells depleted of NudCL.

Discussion

In this communication, we provide evidence that (i) depletion of NudCL inhibits cell growth, causes multiple mitotic defects, and




Fig. 5. NudCL associates with Lis1 and the dynein complex. (A) FLAG-NudCL coimmunoprecipitates with Lis1 and dynein IC. At 40 h after transfection, HeLa cells transfected with control vector or pCMV-FLAG-NudCL were subjected to immunoprecipitation with anti-FLAG antibody. Immunoblotting analyses were performed with anti-FLAG, Lis1, and dynein IC antibodies. (B) FLAG-NudCL and Lis1 are present in the dynein complex. Lysates from HeLa cells transfected with control vector or pCMV-FLAG-NudCL were immunoprecipitated with anti-dynein IC antibody. Immunoprecipitated proteins were immunoblotted with anti-FLAG, Lis1, and dynein IC antibodies.

induces cell death; (ii) NudCL associates with the dynein complex; and (iii) NudCL appears to be involved in the stabilization of dynein IC.

A Role of NudCL in Mitosis. NudCL-depleted cells display a disordered mitotic spindle with chromosome misalignment and fail to separate sister chromatids normally, which is consistent with the accumulation of cells with dumbbell-like nuclei or micronuclei in interphase and elevated G₂ DNA content. These data indicate a dysfunctional kinetochore and partial defects in the mitotic spindle checkpoint, generally consistent, to some extent, with




Fig. 6. Depletion of NudCL induces the degradation of dynein IC. HeLa cells were transfected with either pBS/U6 or pBS/U6-NudCL and pBAGE-puro at a ratio of 7:1. At 24 h after transfection, puromycin was added to select the transfection-positive cells. (A) The degradation of dynein IC in cells depleted of NudCL. HeLa cells harvested at different times as indicated were subjected to immunoblotting analysis. (B) The inhibition of dynein IC degradation in cells depleted of NudCL by MG132, a proteasome inhibitor. At 96 h after transfection, HeLa cells were treated with MG132 for another 12 h and were subjected to immunoblotting analysis.

effects induced by the depletion of dynein IC in various systems (17–19). During mitosis, dynein motors are recruited to kinetochores at prometaphase and drive spindle checkpoint proteins to spindle poles at metaphase to inactivate the spindle checkpoint, which is required for activation of anaphase promoting complex and correct chromosome segregation (18). Mislocalization of the dynein complex from the kinetochores during mitosis in NudCL-depleted cells may lead to mitotic arrest with activation of the spindle checkpoint and defects in chromosome segregation (1, 18, 19).

In general, the recruitment of the γ -tubulin ring complex, dynein/dynactin complex, and other spindle-promoting factors to the pericentriolar material by the dynein complex at late prophase is essential for mitotic spindle formation (20). In NudCL-depleted cells, both γ -tubulin and dynein complex at the spindle poles are obviously decreased during mitosis. We found a major proportion of the dynein complex detached from disordered and elongated spindles, with a loss of spindle pole focus in cells depleted of NudCL, implying an impaired mitotic spindle machinery. A number of studies using various model systems have shown that mitotic spindle length can be influenced by microtubule polymer dynamics, sister-chromatid cohesion, or mitotic motor activity at different levels (21, 22). In the *Xenopus* extract system, the dynein/dynactin complex regulates mitotic spindle length by targeting Kif2a to the spindle poles, which is a microtubule-depolymerizing regulator and plays a key role in bipolar spindle assembly and spindle microtubule length (21). The depletion of dynein IC by the addition of anti-dynein IC antibody into the *Xenopus* extract significantly increases the mitotic spindle length (21). In *Aspergillus*, a γ -tubulin mutant (*mipAR63*) in which NudI (dynein IC) does not localize to the spindle poles also shows a similar phenotype with much longer spindles (23), indicating that γ -tubulin is required for localization of the dynein to the spindle pole. Therefore, the reduction of dynein IC and γ -tubulin at mitotic spindle poles induced by NudCL depletion may contribute to the abnormal elongation of the mitotic spindle. Taken together, the majority of mitotic phenotypes in cells depleted of NudCL suggest that NudCL is involved in the dynein pathway in mammalian cells.

NudCL Is Required to Stabilize Dynein IC. In mammalian cells, NudCL, as well as NudC, interact with Lis1 and the other components of the cytoplasmic dynein complex (4, 10, 11). In *A. nidulans*, extra copies of the *nudF* gene can rescue the *nudC3* mutation phenotype by restoring the protein level of NudF (9), indicating that NudC may be upstream of NudF in *Aspergillus*. However, the protein level of NudF is not changed in *A. nidulans* in which NudC protein is down-regulated (13). Furthermore, mammalian cells individually depleted or codepleted of NudC or NudCL also showed no significant change in the level of Lis1/NudF protein (unpublished data). These data suggest that NudC and its mammalian homologs may not be upstream of NudF/Lis1. Recent data show that NudE may be upstream of NudF in *A. nidulans*, because NudF overproduction effectively rescues the abnormalities induced by deletion of the *nudE* gene (24), and similar results also have been obtained in yeasts and mammalian cells (25, 26).

Unexpectedly, dynein IC, a key scaffold protein for the assembly of dynein/dynactin complex (2), was greatly decreased in NudCL-depleted mammalian cells, implying that NudCL may play a role in stabilizing the dynein complex. This hypothesis is reinforced by the following data: First, in cells depleted of NudCL, dynein IC was mislocalized from its mitotic targeting sites and appeared to aggregate throughout the cytoplasm during mitosis. In interphase, dynein IC appeared as aggregates surrounding the microtubule-organizing center in cells depleted of NudCL, implying possible aggresome formation (15). Importantly, the degradation of dynein IC induced by NudCL deple-

tion was significantly suppressed by MG132, a proteasome inhibitor. Mutations in the gene for cytoplasmic dynein IC, *Dic19C*, in *Drosophila*, result in larval lethality, demonstrating that the dynein IC serves an essential function (27), which was further supported by NudCL depletion-induced cell death reported here. Based on these observations, one possibility is that the dynein IC may be misfolded and is targeted to proteasomes for degradation in NudCL-depleted cells. This interpretation is consistent with the observation that dynein IC has a limited secondary and tertiary structure at near physiological solution conditions and requires other proteins to form a more ordered structure (28, 29).

We note that the nuclear movement domains in all NudC homologues contain a p23 domain that shows sequence similarity to a conserved cochaperone p23 that has a passive chaperone activity to specifically associate with partially folded proteins, preventing their aggregation and maintaining fold-competent conformations (30). Examination of the nuclear movement domain sequences of NudCL reveals that NudCL shares significant homology to p23 at its highly conserved positions (unpublished data), suggesting that NudCL may be involved in a chaperoning process. We speculate that NudCL may have a passive chaperone activity and bind to partially folded dynein ICs, preventing their aggregation until they are completely folded (Fig. 13, which is published as supporting information on the PNAS web site). Further investigation clearly is needed to determine whether NudCL has a passive chaperone activity to dynein IC.

Materials and Methods

Cloning of Human NudCL. To identify human NudCL, the protein sequence of human NudC was used to search the National Center for Biotechnology Information database with TBLASTN. Based on the sequence of an expressed sequence tag (BC035014), one pair of primers, 5'-CGGGAGGCGACATG-GAGCCA-3' and 5'-GGCGAGGGTTTCCTTTCCTTC-3', was designed to clone NudCL by RT-PCR from total RNA extracted from HeLa cells.

Plasmid Construction. Full-length NudCL was subcloned into pGEX-5X-1 (Amersham Pharmacia) and pCMV-Tag2C (Stratagene). The targeting sequence in the construct pBS/U6-NudCL is 5'-GGGCATCAGGAAGTAGAGAAAG-3', corresponding

to the region 375–396 relative to the first nucleotide of the start codon.

Cell Culture, DNA Transfections, and FACS Analyses. HeLa and T98G cells were maintained in DMEM containing 10% FBS. HeLa cells were transfected by GenePORTER transfection reagent (Gene Therapy Systems, San Diego). Propidium iodide staining and cell cycle analysis by using CellQuest were performed as described in ref. 12.

Anti-NudCL Antibody Production. Rabbit polyclonal anti-NudCL antibody was generated by using bacterially expressed GST-NudCL as an antigen (Proteintech, Chicago) and was affinity purified.

Immunoprecipitation and Western Analyses. Immunoprecipitation experiments were performed as described in ref. 11. The immunoprecipitates or total proteins isolated from mammalian cells were subjected to immunoblotting analyses with anti-NudCL, NudC (a gift from Li-yuan Yu-Lee, Baylor College of Medicine, Houston), cyclin B1, extracellular signal-regulated kinase 2 (Santa Cruz Biotechnology), dynein IC (Covance, Berkeley, CA), FLAG, Lis1 (Sigma) or phosphorylated histone H3 (Upstate Biotechnology) primary antibodies, and anti-mouse or anti-rabbit Ig horseradish peroxidase-linked secondary antibodies (Amersham Pharmacia). Immunoblotting analyses with extracellular signal-regulated kinase 2 were used as a loading control.

Immunofluorescence Staining. The cells grown on coverslips were fixed with cold methanol (−20°C) and then stained with anti-dynein IC, α -tubulin, γ -tubulin (Sigma), NudCL antibodies, or anti-CREST (kinetochore) serum (Antibodies, Inc.) for 2 h at room temperature, followed by incubation with either Cy3- or FITC-conjugated anti-mouse or anti-rabbit Ig secondary antibody (Jackson ImmunoResearch) for 40 min. Finally, DNA was stained with DAPI (Sigma). The mounted coverslips were analyzed by confocal fluorescence microscopy (LSM510; Zeiss).

We thank Eleanor Erikson, Ming Lei, and Diana Kornet for critical comments. This work was supported by National Institutes of Health Grant GM59172. R.L.E. is the John F. Drum American Cancer Society Research Professor. T.Z. is supported by Natural Scientific Foundation of Zhejiang Province Grant R205291 from the People's Republic of China.

- Karki, S. & Holzbaur, E. L. (1999) *Curr. Opin. Cell Biol.* **11**, 45–53.
- Vale, R. D. (2003) *Cell* **112**, 467–480.
- Mallik, R. & Gross, S. P. (2004) *Curr. Biol.* **14**, R971–R982.
- Morris, N. R. (2000) *J. Cell Biol.* **148**, 1097–1101.
- Wynshaw-Boris, A. & Gambello, M. J. (2001) *Genes Dev.* **15**, 639–651.
- Zhang, J., Li, S., Fischer, R. & Xiang, X. (2003) *Mol. Biol. Cell* **14**, 1479–1488.
- Vallee, R. B., Tai, C. & Faulkner, N. E. (2001) *Trends Cell Biol.* **11**, 155–160.
- Yan, X., Li, F., Liang, Y., Shen, Y., Zhao, X., Huang, Q. & Zhu, X. (2003) *Mol. Cell Biol.* **23**, 1239–1250.
- Xiang, X., Osmani, A. H., Osmani, S. A., Xin, M. & Morris, N. R. (1995) *Mol. Biol. Cell* **6**, 6297–6310.
- Aumais, J. P., Tunstead, J. R., McNeil, R. S., Schaar, B. T., McConnell, S. K., Lin, S. H., Clark, G. D. & Yu-Lee, L. Y. (2001) *J. Neurosci.* **21**, RC187.
- Zhou, T., Aumais, J., Liu, X., Yu-Lee, L. Y. & Erikson, R. L. (2003) *Dev. Cell* **5**, 127–138.
- Liu, X., Yan, S., Zhou, T., Terada, Y. & Erikson, R. L. (2004) *Oncogene* **23**, 763–776.
- Chiu, Y. H., Xiang, X., Dawe, A. L. & Morris, N. R. (1997) *Mol. Biol. Cell* **8**, 1735–1749.
- Piehl, M., Tulu, U. S., Wadsworth, P. & Cassimeris, L. (2004) *Proc. Natl. Acad. Sci. USA* **101**, 1584–1588.
- Garcia-Mata, R., Gao, Y. S. & Sztul, E. (2002) *Traffic* **3**, 388–396.
- Lee, D. H. & Goldberg, A. L. (1998) *Trends Cell Biol.* **8**, 397–403.
- Gaglio, T., Dionne, M. A. & Compton, D. A. (1997) *J. Cell Biol.* **138**, 1055–1066.
- Howell, B. J., McEwen, B. F., Canman, J. C., Hoffman, D. B., Farrar, E. M., Rieder, C. L. & Salmon, E. D. (2001) *J. Cell Biol.* **155**, 1159–1172.
- Morales-Mulia, S. & Scholey, J. M. (2005) *Mol. Biol. Cell* **16**, 3176–3186.
- Blagden, S. P. & Glover, D. M. (2003) *Nat. Cell Biol.* **5**, 505–511.
- Gaetz, J. & Kapoor, T. M. (2004) *J. Cell Biol.* **166**, 465–471.
- Goshima, G., Wollman, R., Stuurman, N., Scholey, J. M. & Vale, R. D. (2005) *Curr. Biol.* **15**, 1979–1988.
- Li, S., Oakley, C. E., Chen, G., Han, X., Oakley, B. R. & Xiang, X. (2005) *Mol. Biol. Cell* **16**, 3591–3605.
- Efimov, V. P. (2003) *Mol. Biol. Cell* **14**, 871–888.
- Li, J., Lee, W. L. & Cooper, J. A. (2005) *Nat. Cell Biol.* **7**, 686–690.
- Shu, T., Ayala, R., Nguyen, M. D., Xie, Z., Gleeson, J. G. & Tsai, L. H. (2004) *Neuron* **44**, 263–277.
- Boylan, K. L. M. & Hays, T. S. (2002) *Genetics* **162**, 1211–1220.
- Makokha, M., Hare, M., Li, M., Hays, T. & Barbar, E. (2002) *Biochemistry* **41**, 4302–4311.
- Nyarko, A., Hare, M., Hays, T. S. & Barbar, E. (2004) *Biochemistry* **43**, 15595–15603.
- Garcia-Ranea, J. A., Mirey, G., Camonis, J. & Valencia, A. (2002) *FEBS Lett.* **529**, 162–167.